Omid Sadr-Azodi1,2,3, Peter Konings4, Nele Brusselaers4. 1. Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 2. Department of Surgery, Eskilstuna County Hospital, Eskilstuna, Sweden. 3. Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden. 4. Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing to small studies and lack of proper study design. METHODS: This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July 2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity, and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT duration on pancreatic cancer development was calculated using multivariable Poisson regression. RESULTS: There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011%) ever-users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had a 23% reduced risk (OR 0.77; 95% CI: 0.68-0.87) of pancreatic cancer. This risk decreased by 35% (incidence rate ratio (IRR) 0.65; 95% CI: 0.33-1.27) in women who used MHT 1-2 years and by 60% (IRR 0.40; 95% CI: 0.18-0.88) in women who used MHT ≥ 3 years compared to women with <1 year of MHT use. The type of MHT did not change the results. CONCLUSION: Systemic MHT use might reduce the risk of pancreatic cancer.
BACKGROUND: The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing to small studies and lack of proper study design. METHODS: This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July 2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity, and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT duration on pancreatic cancer development was calculated using multivariable Poisson regression. RESULTS: There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011%) ever-users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had a 23% reduced risk (OR 0.77; 95% CI: 0.68-0.87) of pancreatic cancer. This risk decreased by 35% (incidence rate ratio (IRR) 0.65; 95% CI: 0.33-1.27) in women who used MHT 1-2 years and by 60% (IRR 0.40; 95% CI: 0.18-0.88) in women who used MHT ≥ 3 years compared to women with <1 year of MHT use. The type of MHT did not change the results. CONCLUSION: Systemic MHT use might reduce the risk of pancreatic cancer.
Entities:
Keywords:
Menopausal hormone therapy; epidemiology; etiology; pancreatic cancer; population-based study
Authors: Eunjung Lee; Pamela L Horn-Ross; Rudolph P Rull; Susan L Neuhausen; Hoda Anton-Culver; Giske Ursin; Katherine D Henderson; Leslie Bernstein Journal: Am J Epidemiol Date: 2013-09-05 Impact factor: 4.897
Authors: Petra G A van Boeckel; Hendriek C Boshuizen; Peter D Siersema; Alina Vrieling; Anton E Kunst; Weimin Ye; Malin Sund; Dominique S Michaud; Valentina Gallo; Elizabeth A Spencer; Antonia Trichopoulou; Vasiliki Benetou; Philippos Orfanos; Lluis Cirera; Eric J Duell; Sabine Rohrmann; Silke Hemann; Giovanni Masala; Jonas Manjer; Amalia Mattiello; Bjorn Lindkvist; María-José Sánchez; Valeria Pala; Petra H M Peeters; Tonje Braaten; Anne Tjonneland; Susanne Oksbjerg Dalton; Nerea Larranaga; Miren Dorronsoro; Kim Overvad; Anne-Kathrin Illner; Eva Ardanaz; M Marron; K Straif; E Riboli; B Bueno-de-Mesquita Journal: Cancer Epidemiol Date: 2010-09-15 Impact factor: 2.984
Authors: Halcyon G Skinner; Dominique S Michaud; Graham A Colditz; Edward L Giovannucci; Meir J Stampfer; Walter C Willett; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-05 Impact factor: 4.254
Authors: G Corrao; A Zambon; V Conti; F Nicotra; C La Vecchia; C Fornari; G Cesana; P Contiero; G Tagliabue; R E Nappi; L Merlino Journal: Ann Oncol Date: 2007-09-04 Impact factor: 32.976
Authors: Alina Vrieling; H Bas Bueno-de-Mesquita; Hendriek C Boshuizen; Dominique S Michaud; Marianne T Severinsen; Kim Overvad; Anja Olsen; Anne Tjønneland; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Sabine Rohrmann; Heiner Boeing; Ute Nöthlings; Antonia Trichopoulou; Eftihia Moutsiou; Vardis Dilis; Domenico Palli; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Paolo Vineis; Carla H van Gils; Petra H M Peeters; Eiliv Lund; Inger T Gram; Laudina Rodríguez; Antonio Agudo; Nerea Larrañaga; María-José Sánchez; Carmen Navarro; Aurelio Barricarte; Jonas Manjer; Björn Lindkvist; Malin Sund; Weimin Ye; Sheila Bingham; Kay-Tee Khaw; Andrew Roddam; Tim Key; Paolo Boffetta; Eric J Duell; Mazda Jenab; Valentina Gallo; Elio Riboli Journal: Int J Cancer Date: 2010-05-15 Impact factor: 7.396
Authors: An-Chi Lo; Amr S Soliman; Nabih El-Ghawalby; Mohamed Abdel-Wahab; Omar Fathy; Hussein M Khaled; Sherif Omar; Stanley R Hamilton; Joel K Greenson; James L Abbruzzese Journal: Pancreas Date: 2007-08 Impact factor: 3.327
Authors: Esther N Pijnappel; Melinda Schuurman; Anna D Wagner; Judith de Vos-Geelen; Lydia G M van der Geest; Jan-Willem B de Groot; Bas Groot Koerkamp; Ignace H J T de Hingh; Marjolein Y V Homs; Geert-Jan Creemers; Geert A Cirkel; Hjalmar C van Santvoort; Olivier R Busch; Marc G Besselink; Casper H J van Eijck; Johanna W Wilmink; Hanneke W M van Laarhoven Journal: Front Oncol Date: 2022-03-24 Impact factor: 6.244